Relmada Therapeutics Inc (NASDAQ:RLMD) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders. The company is currently making headlines due to its promising drug candidate, NDV-01, which targets high-risk non-muscle invasive bladder cancer (NMIBC). This focus on NMIBC sets Relmada apart from competitors who may not be targeting this specific cancer type.
On March 13, 2026, Uy Ear from Mizuho Securities set a price target of $10 for RLMD, while the stock was trading at $5.91. This suggests a potential upside of approximately 69.2%. Mizuho's "Outperform" rating indicates confidence in RLMD's future performance, viewing the recent price pullback as a buying opportunity. This optimism is supported by the company's recent achievements.
Relmada's stock surged by 42% within a week, driven by positive data from a mid-stage study of NDV-01. The study showed a 12-month complete response rate of 76%, with even higher rates at earlier intervals. These results have encouraged Relmada to plan phase III RESCUE studies, expected to start in mid-2026. This progress highlights the potential of NDV-01 in treating NMIBC.
Despite the recent stock surge, RLMD's current price is $5.91, reflecting a 3.90% decrease or $0.24 drop. The stock has fluctuated between $5.82 and $6.45 during the trading day. Over the past year, RLMD has seen a high of $7.51 and a low of $0.24. The company's market capitalization is approximately $433.4 million, with a trading volume of 1,255,235 shares.
The promising data from NDV-01 and the planned phase III studies could drive future growth for Relmada. As the company continues to advance its drug development, investors may find the current stock price an attractive entry point, especially with Mizuho's optimistic outlook.
